Study to Evaluate Tulisokibart for Hidradenitis Suppurativa (MK-7240-012)
Status:
RECRUITING
Trial end date:
2029-01-22
Target enrollment:
Participant gender:
Summary
This is a phase 2b randomized, double-blind, placebo-controlled study of the safety and efficacy of tulisokibart in participants with moderate to severe hidradenitis suppurativa. The primary hypothesis is that at least 1 dose of tulisokibart is superior to placebo with respect to the proportion of participants achieving a 50% reduction in Hidradenitis Suppurativa Clinical Response (HiSCR50) at Week 16 (ie, at end of double-blind treatment).